ERBB4 exonic deletions on chromosome 2q34 in patients with intellectual disability or epilepsy

Zerin Hyder, Wim Van Paesschen, Ataf Sabir, Francis H Sansbury, Katherine B Burke, Naz Khan, Kate E. Chandler, Nicola S Cooper, Ronnie Wright, Edward McHale, Hilde Van Esch, Siddharth Banka

Research output: Contribution to journalArticlepeer-review


ERBB4 encodes the tyrosine kinase receptor HER4, a critical regulator of normal cell function and neurodevelopmental processes in the brain. One of the key ligands of HER4 is neureglin-1 (NRG1), and the HER4-NRG1 signalling pathway is essential in neural crest cell migration, and neuronal differentiation. Pharmacological inactivation of HER4 has been shown to hasten the progression of epileptogenesis in rodent models, and heterozygous ERBB4 null mice are shown to have cognitive deficits and delayed motor development. Thus far there is only a single case report in the literature of a heterozygous ERBB4 deletion in a patient with intellectual disability (ID). We identified nine subjects from five unrelated families with chromosome 2q34 deletions, resulting in heterozygous intragenic loss of multiple exons of ERBB4, associated with either non-syndromic ID or generalised epilepsy. In one family, the deletion segregated with ID in five affected relatives. Overall, this case series further supports that haploinsufficiency of ERBB4 leads to non-syndromic intellectual disability or epilepsy.

Original languageEnglish
JournalEuropean journal of human genetics : EJHG
Publication statusPublished - 18 Feb 2021


Dive into the research topics of 'ERBB4 exonic deletions on chromosome 2q34 in patients with intellectual disability or epilepsy'. Together they form a unique fingerprint.

Cite this